Are We Chasing Youth… or Borrowing From Our Future?

What a New Nature Aging Commentary Reveals About the Hidden Risks of “Anti-Aging” Interventions — and How ERM Helps Us See the Full Picture

A new commentary in Nature Aging — “Balancing the Promise and Risks of Geroscience Interventions” — has sparked an important conversation in the longevity world. The authors warn that while anti-aging science is advancing faster than ever, our enthusiasm may be outrunning our understanding.

One figure from the paper captures the problem perfectly.

It shows the current trajectory of aging-intervention research:

1. We develop biomarkers.

2. We test interventions using those biomarkers.

3. Early results look promising.

4. Public uptake accelerates.

5. Years later, we finally learn whether the intervention helped… or caused harm.

In other words: short-term improvements don’t guarantee long-term benefits — and may hide long-term risks.

And right now, this is exactly what we’re seeing in the real world.

The Problem With “Promising Results”: When Short-Term Wins Hide Long-Term Trade-Offs

The Nature Aging commentary argues that aging is not a single pathway but a complex, multi-system balancing act — and our tools for measuring it are still incomplete. This creates a blind spot: an intervention may improve one biomarker while quietly disturbing another.

Here are real-world examples:

1. GLP-1 RAs (Semaglutide, Tirzepatide):

A Case of “Everything Looks Better… Until It Doesn’t”

Millions of people now use GLP-1 medications for weight loss and “healthspan.”In the short term, their biomarkers look fantastic:

• lower glucose

• less inflammation

• lower body weight

• improved lipid profiles

But then deeper questions emerged:

• 50–60% of weight loss is lean mass, not fat

• muscle protein turnover decreases

• older adults experience functional decline

• long-term appetite suppression resembles low-grade undernutrition

• insulin + glucagon suppression may impair metabolic flexibility

Nothing about these concerns shows up in the early biomarkers.

This is exactly the “temporal discordance” the commentary warns about: benefits now, risks that appear years later.

2. NAD+ boosters:

Younger epigenetic age, but at what cost?

NAD precursors can make epigenetic clocks “look younger” and improve metabolic markers — but animal studies show:

• disrupted methylation fidelity

• increased instability in genetic repair

• impaired stem cell differentiation at high doses

Again: short-term biomarker wins≠long-term resilience.

3. Rapamycin:

Better aging clocks, worse immune function**

Rapamycin improves several aging biomarkers and extends lifespan in rodents.

But humans experience:

• increased infection risk

• impaired wound healing

• metabolic disturbances

These changes rarely appear in the “aging clocks” people use to evaluate success.

4. Senolytics:

Killing “bad cells” can also remove protective defenses**

Senolytics reduce senescence markers and improve inflammation signatures.

But senescent cells also:

• suppress tumor formation

• coordinate tissue repair

• prevent unchecked cell proliferation

Removing them too aggressively may increase long-term cancer risk — a perfect example of the trade-offs highlighted in the figure.

The Core Message of the Figure:

“Biomarkers Are Not the Whole Story.”

The flowchart in the article shows why the field is vulnerable:

→ We rely on biomarkers because real aging unfolds over decades.

→ We assume improvements today will still look good years later.

→ Interventions spread widely long before we know the truth.

→ If biomarker improvements are misleading, harm will only appear in the distant future.

This is not a theoretical problem.

It is already happening.

How the ERM Framework Helps Solve These Problems

The ERM (Exposure-Related Malnutrition) framework offers a way to understand and anticipate the risks that the commentary outlines.

It reframes aging not as isolated “hallmarks,” but as a bioenergetic imbalance:

when chronic stress, metabolic load, inflammation, toxic exposures, and under-recovery exceed the body’s ability to restore itself, a state of energy scarcity develops — even in people who appear well-fed.

This insight changes everything.

1. ERM explains hidden trade-offs

Under ERM, many short-term “improvements” actually reflect:

• lower metabolic throughput

• suppressed repair mechanisms

• decreased anabolic activity

• reduced immune readiness

• conservation-mode physiology

In other words: the body is spending less because it has less to spend.

This can make biomarkers look better while resilience quietly erodes.

Exactly the risk described in the Nature Aging commentary.

2. ERM provides a better biomarker strategy

ERM emphasizes biomarkers of:

• energy availability (mitochondrial capacity, ATP/OXPHOS balance)

• energy allocation (GDF-15, muscle turnover, immune energetics)

• recovery and resolution (inflammation rebound curves, redox recovery)

• cellular repair sufficiency (telomerase activity, genomic maintenance)

These domains directly address the limitations in the figure:

• multi-system coverage

• detection of trade-offs

• early identification of long-term harm

ERM provides the missing measurement layer.

3. ERM helps distinguish adaptive improvement from metabolic suppression

Many interventions — especially GLP-1s, drastic calorie restriction, and chronic rapamycin use — produce improvements by shifting the body into a low-energy state, not by enhancing resilience.

ERM directly identifies this metabolic signature.

This solves the figure’s biggest challenge: biomarkers may improve while the organism weakens.

4. ERM reframes aging as the accumulation of metabolic debt

The commentary argues that aging is ambiguous and multifactorial.

ERM explains this by showing:

• each stressor increases energy demand

• every incomplete recovery leaves a small deficit

• over years, these deficits accumulate

• resilience slowly erodes

• aging accelerates as bioenergetic debt deepens

This provides the missing unifying mechanism for the field’s concerns.

The Bottom Line:

Improving a biomarker is not the same as rebuilding resilience.**

The Nature Aging commentary warns us that:

anti-aging interventions may deliver early improvement while borrowing from future health.

The ERM framework helps us see why — and provides tools to measure aging not as a number on a clock, but as a whole-body bioenergetic balance.

Until we measure and restore that balance,“anti-aging” may simply be shifting costs from today to tomorrow.

And longevity should not be financed like debt

Cohen, A. A., Beard, J. R., Ferrucci, L., Fülöp, T., Gladyshev, V. N., Moqri, M., Olde Rikkert, M. G. M., & Picard, M. (2025). Balancing the promise and risks of geroscience interventions. Nature Aging, 5, 1–10. https://doi.org/10.1038/s43587-024-00788-9